Modus Therapeutics

Founded in 2011, Modus Therapeutics AB specializes in therapeutic solutions for critical conditions. The company, headquartered in Stockholm, Sweden, has undergone strategic pivots to enhance its focus on sevuparin, a polysaccharide product.Modus Therapeutics is primarily focused on developing its proprietary polysaccharide product, sevuparin, as a novel therapeutic solution for critical healthcare challenges, particularly those associated with severe conditions such as sepsis, septic shock, and severe systemic inflammation, including severe malaria and anemia related to chronic inflammation, like chronic kidney disease (CKD). Sevuparin operates by modulating the immune response and reducing systemic inflammation, aiming to provide clinical benefits to patients suffering from these high unmet medical needs. The product is designed for use in both hospital and outpatient settings, targeting healthcare providers, hospitals, and specialty clinics across various geographical markets, including Europe, North America, and select regions in Asia.4. The company derives its revenue primarily from the commercialization of sevuparin, engaging in B2B transactions with healthcare providers and institutions that purchase the product for patient care. The company is also exploring opportunities to expand its market presence in Europe and North America, with plans to enhance the therapeutic applications of sevuparin in these regions.

1. Series A

   Jul 13, 2018

   Amount

   $16M

   Investors

   Locked